Get the Stockscreener App
236.28
0.60%
1.40
Jazz Pharmaceuticals Plc stock is traded at $236.28, with a volume of 551.20K.
It is up +0.60% in the last 24 hours and down -7.15% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$234.88
Open:
$235.82
24h Volume:
551.20K
Relative Volume:
0.64
Market Cap:
$15.34B
Revenue:
$4.44B
Net Income/Loss:
$29.49M
P/E Ratio:
-12,841.30
EPS:
-0.0184
Net Cash Flow:
$1.19B
1W Performance:
-3.10%
1M Performance:
-7.15%
6M Performance:
+27.71%
1Y Performance:
+82.33%
1-Day Range:
$232.00
$236.52
1-Week Range:
$231.59
$244.55
52-Week Range:
$125.78
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
236.28 | 15.34B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals plc (JAZZ) Stock forecasts - Yahoo Finance UK
Jazz Pharmaceuticals stock reports record Q2 revenue growth - AD HOC NEWS
JAZZ Reinstated by Goldman Sachs -- Price Target Set at $337 - GuruFocus
Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating By Investing.com - Investing.com UK
JAZZ Looks 56.8% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Jazz Pharmaceuticals PLC (J7Z.HA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - finance.yahoo.com
Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033 - TradingView
Five more years to repay its loans: Jazz Pharmaceuticals (JAZZ) also lowers borrowing margins. - Stock Titan
Jazz Pharmaceuticals (JAZZ) Gains Put Its Valuation Story Back In Focus - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Chumi Khurana Recognized by the Asian American Business Development Center in Partnership With America250Jazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals plc (JAZZ) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Jazz Pharmaceuticals stock holds near USD 241.46 as results shape the outlook - AD HOC NEWS
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: A Biotech Powerhouse with 20% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - finance.yahoo.com
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - finance.yahoo.com
What Makes the Latest Jazz Pharmaceuticals (JAZZ) Story Different? - Kalkine Media
Jazz Pharmaceuticals PLC (JAZZ) Stock Price Target & Forecast - TradingKey
Ajit Baid Joins Jazz Pharmaceuticals as Executive Director, Head of Marketing – EMD Franchise - hrtoday.in
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? - The Motley Fool
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet - finance.yahoo.com
Jazz Pharmaceuticals PLC at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences - BioBuzz
Jazz Pharmaceuticals PLC at Deutsche Bank HealthCare Summit Transcript - GuruFocus
Form 8K Jazz Pharmaceuticals plc For: 15 September By Investing.com - Investing.com South Africa
JAZZ: Oncology and portfolio growth drive raised guidance, with zanidatamab leading future expansion - TradingView
Jazz Pharmaceuticals completes Actio Biosciences acquisition - Investing.com
Jazz Pharmaceuticals completes Actio Biosciences acquisition By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: An 18% Upside Potential Beckons Investors - DirectorsTalk Interviews
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):